Skip to main content
. 2022 Jan 27;11(3):438. doi: 10.3390/cells11030438

Figure 3.

Figure 3

Tumor-resident basophils and clinical outcomes in different breast cancer subtypes. Survival outcome analysis was performed using the Kaplan–Meier (KM) Plotter online tool (https://kmplot.com/analysis/, accessed on 7 December 2021) [71]. Gene expression analyses of tumor-resident basophils (CD123, CCR3, and FcεRI) and activated basophil signatures (CD123, CCR3, FcεRI, CD63, CD203c ± tryptase) were performed. Patient survival outcomes were analyzed over 60 months. Groups of patients were selected based on combined gene expression levels of selected basophil markers in tumor lesions, into top tertile (T3) and lower tertile (T1). Patients in the middle tertile (T2) were excluded. Markers (Gene Probe ID): CD123 (206148_at); CCR3 (208304_at); FcεRI (211734_s_at); CD63 (200663_at); CD203c (232737_S_at) and tryptase (210084_x_at). Summary of n numbers (number of individuals at risk) can be found in Supplementary Table S3. Data sourced though mRNA gene chip. p values: * = p < 0.05.